Join to View Full Profile
6362 144th AveHolland, MI 49423
Phone+1 201-965-9573
Are you Dr. Bertolino?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Arthur Bertolino, MD is a board certified dermatologist in Holland, Michigan. He is currently licensed to practice medicine in Michigan.
Education & Training
NYU Grossman School of MedicineResidency, Dermatology, 1983 - 1985- NYU Grossman School of MedicineResidency, Internal Medicine, 1982 - 1983
- NYU Grossman School of MedicineResidency, Dermatology, 1981 - 1982
Johns Hopkins University School of MedicineInternship, Transitional Year, 1980 - 1981- Johns Hopkins University School of MedicineClass of 1980
Certifications & Licensure
MI State Medical License 2003 - 2026
American Board of Dermatology Dermatology
Publications & Presentations
PubMed
- 257 citationsEfficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomi...Iain B. McInnes, Joachim Sieper, Juergen Braun, Paul Emery, Désirée van der Heijde
Annals of the Rheumatic Diseases. 2014-02-01 - 434 citationsAnti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trialDominique Baeten, Xenofon Baraliakos, Jürgen Braun, Joachim Sieper, Paul Emery
Lancet. 2013-11-23 - 1149 citationsSecukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trialWolfgang Hueber, Bruce E. Sands, Steve Lewitzky, Marc Vandemeulebroecke, Walter Reinisch
Gut. 2012-12-01
Press Mentions
Technoderma Medicines Completes Positive Ph2a Proof- of Concept Trial with Topical TDM-180935 Ointment for Atopic DermatitisJanuary 6th, 2025
Innovation Pharmaceuticals Partnering Provides Momentum for Inflammatory Bowel Disease Programs, Targeting a Substantial and Prized Market with a Large Unmet Patient NeedOctober 14th, 2019
Innovation Pharmaceuticals Announces License Agreement with Alfasigma S.p.A. For the Development and Commercialization of Brilacidin in Ulcerative Proctitis/Ulcerative ProctosigmoiditisJuly 22nd, 2019- Join now to see all
Grant Support
- CTO1681 to prevent and mitigate cytokine release syndrome in CAR T-cell recipientsCYTOAGENTS, INC.2024–2026
